Page last updated: 2024-11-12

azastene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

azastene: inhibitor of ovarian & adrenal steroidogenesis in rats; progesterone antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11725766
CHEMBL ID2103987
SCHEMBL ID2110561
MeSH IDM0067481

Synonyms (27)

Synonym
win 17625
17beta-hydroxy-4,4,17alpha-trimethylandrost-5-en-(2,3d)-isoxazole
4,4,17-trimethylandrosta-2,5-dieno(2,3-d)isoxazol-17beta-ol
androsta-2,5-dieno(2,3-d)isoxazol-17-ol, 4,4,17-trimethyl-, (17beta)-
azastenum [inn-latin]
4,4,17-alpha-trimethylandrost-5-eno(2,3-d)isoxazol-17-ol
(17beta)-4,4,17-trimethylandrosta-2,5-diene(3,2-d)isoxazol-17-ol
azasteno [inn-spanish]
isoxazol
azastene
win-17625
13074-00-5
unii-1xa84itl1h
azasteno
azastenum
azastene [inn]
1xa84itl1h ,
CHEMBL2103987
4,4,17-trimethylandrosta-2,5-dieno(2,3-d)isoxazol-17b-ol
4,4,17-trimethylandrosta-2,5-dieno[2,3-d]isoxazol-17beta-ol
androsta-2,5-dieno(2,3-d)isoxazol-17-ol, 4,4,17-trimethyl-, (17.beta.)-
SCHEMBL2110561
Q15633983
4-hydroxy-n,n-diphenyl-(4r)-2-pentynamide>98%byhplc,>98%ee
(1s,2r,13r,14s,17s,18s)-2,9,9,17,18-pentamethyl-7-oxa-6-azapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4(8),5,10-trien-17-ol
(17beta)-4,4,17-trimethylandrosta-2,5-dieno[2,3-d]isoxazol-17-ol
DTXSID801180403
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (34)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (29.41)18.7374
1990's3 (8.82)18.2507
2000's5 (14.71)29.6817
2010's8 (23.53)24.3611
2020's8 (23.53)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.32

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.32 (24.57)
Research Supply Index3.58 (2.92)
Research Growth Index4.90 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.32)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.86%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other34 (97.14%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]